- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 328
Unit DX marks $25.5m in portfolio funding
Members of science incubator Unit DX have obtained $25.5m of capital altogether since launch in 2017, with many of its residents hailing from University of Bristol.
May 21, 2019Google places LowRisc bet
Cambridge open source hardware spinout LowRisc has been backed by Alphabet's Google, which has sent two representatives to its board of directors.
May 21, 2019Rinri rings in $1.8m seed round
Sheffield cell therapy spinout Rinri secured corporate backing from Boehringer Ingelheim and UCB in a seed round that will drive work on stem cell-based treatments for hearing loss.
May 21, 2019Prowler.io pounces on $24m
CIC has returned to supply AI forecasting platform Prowler.io with series B capital and help take the company's overall funding to $39m.
May 21, 2019GetYourGuide goes to $484m series E
ETH Zurich spinout GetYourGuide secured $484m in a round led by SoftBank Vision Fund that took its total funding past $650m.
May 21, 2019Prowler.io pounces on $24m
Pearson, Tencent and Mandatum Life helped supply the AI forecasting platform developer with series B capital that took its total funding to $39m.
May 21, 2019Storm attracts more series A funding
M Ventures, Pfizer Ventures and Taiho Ventures all returned to help boost cancer drug developer Storm Therapeutics' series A round to $38.2m.
May 20, 2019UCEF IV binds to PolyProx
The Parkwalk-managed co-investment fund has supplied Cambridge cancer therapy spinout PolyProx Therapeutics with capital, augmenting a $4.4m seed round for the latter announced earlier this month.
May 20, 2019Big deal: Syncona composes Quell with $46m series A
Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.
May 20, 2019Storm's series A continues to resound with investors
Cambridge's cancer drug spinout Storm Therapeutics convinced its existing investors to join new participant Seroba Life Sciences for a second extension that brought its series A total to $38.2m.
May 20, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


